Clinical Trials


Energy Expenditure of People Living With HIV/AIDS

This study has been completed
University of Sao Paulo General Hospital

Fundação de Amparo à Pesquisa do Estado de São Paulo

Information provided by (Responsible Party)
University of Sao Paulo General Hospital Identifier

First received: August 4, 2015
Last updated: August 20, 2015
Last Verified: August 2015
History of Changes


Background: Several studies have reported increased resting energy expenditure (REE) in people living with HIV/AIDS possibly due to changes in body composition that occurs in HIV lipodystrophy syndrome.

The aim of this study was to evaluate the influence of the use of lipid-lowering drugs in resting energy expenditure (REE) and total energy expenditure (TEE) in patients seropositive for HIV in treatment of lipodystrophy.

Condition Intervention
HIV Lipodystrophy Syndrome

Drug : use of lipid-lowering drugs.

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Influence of Lipid-lowering Drugs in Patients Seropositive for HIV With Lipodystrophy in Resting Energy Expenditure and Total Energy Expenditure

Further study details as provided by University of Sao Paulo General Hospital:

Primary Outcome Measures

  • Total Energy Expenditure (kcal/d) [ Time Frame: 14 day ]
  • Resting Energy Expenditure (kcal/d) [ Time Frame: 1 day ]
Secondary Outcome Measures:
  • Correlation between doubly labeled water and accelerometer to measure total energy expenditure (ICC, 95% CI) [ Time Frame: 14 days ]

Biospecimen Retention: Samples With DNA

Enrollment: 45
Study Start Date: March 2013
Study Completion Date: November 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
Drug: use of lipid-lowering drugs.

The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.

Other Name: statins and fibrates

Detailed Description:

REE was measured by indirect calorimetry.
TEE was measured by doubly labeled water (DLW) technique and an activity monitor based on accelerometry (AM).



Ages Eligible for Study: 18 Years to 60 Years  
Sexes Eligible for Study: Male  
Accepts Healthy Volunteers: No  
Sampling Method: Probability Sample  

Study Population

Men previously diagnosed with HIV infection, on antiretroviral therapy.


Inclusion Criteria:

  • Use of antiretroviral therapy for at least 4 months
  • A cluster of differentiation 4 (CD4) T-cell count of >200 cells/mm3
  • Use of lipid-lowering drugs for at least 1 month (group HIV-seropositive with lipodystrophy and use of lipid-lowering)

Exclusion Criteria:
  • Signs or symptoms of opportunistic infections
  • Thyroid disease

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02530827

Sponsors and Collaborators

University of Sao Paulo General Hospital
Fundação de Amparo à Pesquisa do Estado de São Paulo
More Information

More Information

Responsible Party: University of Sao Paulo General Hospital Identifier: NCT02530827   History of Changes  
Other Study ID Numbers: CAAE 01848612.1.0000.5440  
Study First Received: August 4, 2015  
Last Updated: August 20, 2015  

Keywords provided by University of Sao Paulo General Hospital:

energy expenditure
doubly labeled water
lipodystrophy syndrome.

Additional relevant MeSH terms:
HIV-Associated Lipodystrophy Syndrome
Hypolipidemic Agents processed this data on June 02, 2020
This information is provided by